Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators
Authors
Keywords
-
Journal
JAMA Oncology
Volume -, Issue -, Pages e213428
Publisher
American Medical Association (AMA)
Online
2021-08-26
DOI
10.1001/jamaoncol.2021.3428
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
- (2020) Laura M Spring et al. LANCET
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study
- (2020) Jae Ho Jeong et al. EUROPEAN JOURNAL OF CANCER
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Targeted therapy for premenopausal women with HR+, HER2- advanced breast cancer: focus on special considerations and latest advances
- (2018) Aditya Bardia et al. CLINICAL CANCER RESEARCH
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA‐3 Results
- (2017) Sibylle Loibl et al. ONCOLOGIST
- Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer
- (2017) Kazuhiro Araki et al. Breast Cancer
- Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival
- (2016) Ann H. Partridge et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2
- (2016) Gabriel N. Hortobagyi et al. JOURNAL OF CLINICAL ONCOLOGY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Breast cancer in China
- (2014) Lei Fan et al. LANCET ONCOLOGY
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
- (2013) Denise A. Yardley et al. ADVANCES IN THERAPY
- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling
- (2012) Hatem A. Azim et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started